These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6240665)

  • 1. Normal and abnormal determinants of dopamine receptor ontogeny in the central nervous system.
    Feigenbaum JJ; Yanai J
    Prog Neurobiol; 1984; 23(3):191-225. PubMed ID: 6240665
    [No Abstract]   [Full Text] [Related]  

  • 2. The classification of dopamine receptors: relationship to radioligand binding.
    Creese I; Sibley DR; Hamblin MW; Leff SE
    Annu Rev Neurosci; 1983; 6():43-71. PubMed ID: 6220666
    [No Abstract]   [Full Text] [Related]  

  • 3. Functional interactive effects of D1 and D2 dopamine receptor blockade.
    Salama AI; Saller CF
    Adv Exp Med Biol; 1986; 204():137-50. PubMed ID: 2947425
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
    Hess EJ; Albers LJ; Le H; Creese I
    J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Different effects on dopamine receptors D1 and D2 following long-term usage of L-dopa].
    Wei D
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1991 Apr; 24(2):104-7, 125. PubMed ID: 1830547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pathophysiological functions mediated by D1 dopamine receptors.
    Goldstein M; Kuga S; Shimizu Y; Meller E
    Adv Exp Med Biol; 1986; 204():189-95. PubMed ID: 2947428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enantiomeric analogues of SCH 23390 as new probes for behavioral interactions between D1 and D2 dopaminergic function.
    Waddington JL; Molloy AG; O'Boyle KM; Mashurano M
    Adv Exp Med Biol; 1986; 204():125-36. PubMed ID: 2947424
    [No Abstract]   [Full Text] [Related]  

  • 8. Depletion of dopamine binding sites and changes in dopamine and dihydroxyphenylacetic acid levels in 17- and 90-day-old rat striatum after irreversible receptor antagonism.
    Crawford CA; McDougall SA; Rowlett JK; Bardo MT
    Neurosci Lett; 1992 Mar; 137(2):265-9. PubMed ID: 1350079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinolinic acid lesions of rat striatum abolish D1- and D2-dopamine receptor-mediated catalepsy.
    Calderon SF; Sanberg PR; Norman AB
    Brain Res; 1988 May; 450(1-2):403-7. PubMed ID: 2969764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. beta-Adrenergic receptor-sensitive adenosine cyclic 3',5'-monophosphate accumulation in homogenates of the rat corpus striatum. A comparison with the dopamine receptor-coupled adenylate cyclase.
    Harris JE
    Biochem Pharmacol; 1978; 27(24):2919-25. PubMed ID: 216372
    [No Abstract]   [Full Text] [Related]  

  • 11. Schizophrenia: D4 receptor elevation. What does it mean?
    Seeman MV
    J Psychiatry Neurosci; 1994 May; 19(3):171-6. PubMed ID: 7913338
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of D1 and D2 dopamine receptors in oral stereotypy induced by dopaminergic stimulation of the ventrolateral striatum.
    Delfs JM; Kelley AE
    Neuroscience; 1990; 39(1):59-67. PubMed ID: 1982467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional changes of striatal dopamine receptors following denervation by 6-hydroxydopamine and fetal mesencephalic grafts in the rat.
    Gagnon C; Bédard PJ; Rioux L; Gaudin D; Martinoli MG; Pelletier G; Di Paolo T
    Brain Res; 1991 Sep; 558(2):251-63. PubMed ID: 1838295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK; Manzino L; Heikkila RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parallel decrease in the density of dopamine D1 and D2 receptors in corpus striatum of rats from 3 to 25 months of age.
    Hyttel J
    Pharmacol Toxicol; 1989 Jan; 64(1):55-7. PubMed ID: 2526948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D-1 and D-2 receptors in relation to reward and performance: a case for the D-1 receptor as a primary site of therapeutic action of neuroleptic drugs.
    Miller R; Wickens JR; Beninger RJ
    Prog Neurobiol; 1990; 34(2):143-83. PubMed ID: 1969668
    [No Abstract]   [Full Text] [Related]  

  • 18. Topography of dopamine behaviours mediated by D1 and D2 receptors revealed by intrastriatal injection of SKF 38393, lisuride and apomorphine in rats with a unilateral 6-hydroxydopamine-induced lesion.
    Fletcher GH; Starr MS
    Neuroscience; 1987 Feb; 20(2):589-97. PubMed ID: 2953990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dopamine D1 receptor: biochemical and behavioral aspects.
    Andersen PH; Nielsen EB
    Adv Exp Med Biol; 1986; 204():73-91. PubMed ID: 2878580
    [No Abstract]   [Full Text] [Related]  

  • 20. Interaction of D1 and D2 dopamine receptors in the expression of dopamine agonist induced behaviors.
    Braun AR; Barone P; Chase TN
    Adv Exp Med Biol; 1986; 204():151-66. PubMed ID: 2947426
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.